Laurent Audoly

Laurent is a serial biotech entrepreneur and senior executive in the Life Sciences industry. He is co-founder of several biotech companies and is the CEO & Chairman of Parthenon Therapeutics, a precision oncology biotech based in Boston. He has completed numerous pharma/biotech transactions both on the buy and sell-side.

Prior to founding biotechs, Laurent led business and R&D functions across different companies within the U.S. and E.U. including, his roles as CEO of Kymera Therapeutics, head of R&D with Pierre Fabre Pharmaceuticals, and positions of increasing leadership responsibilities on the business and science fronts. At Pfizer, Merck, and Pieris, Laurent contributed to the advancement of 21 drug candidates into clinical development across multiple disease areas and modalities.

Laurent has also led or contributed to the identification and development of seven novel medicines (Xeljanz®, Hemangiol®, Javlor®, Renflexis®, Brenzys®, Ontruzant®, Hadlima® – biologics and small molecules) addressing unmet medical needs across multiple disease areas.

Laurent is an inventor and authored over 70 papers and patents.  He studied chemistry and pharmacology and received his doctorate from Vanderbilt University. He completed postdoctoral training at UNC/Chapel Hill and Duke universities, where he also received an American Heart Association Fellowship.